Ignite Creation Date:
2024-05-05 @ 11:27 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043888
Status:
COMPLETED
Last Update Posted:
2013-02-12
First Post:
2002-08-14
Brief Title:
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase IIIbIV Randomized Open Label Multicenter Pilot Trial to Explore the Safety and Tolerability of GW433908 - Ritonavir 1400mg Twice Daily or 700mg100mg Twice Daily When Used in Combination With a Zidovudine-containing Regimen TRIZIVIR or COMBIVIR Twice Daily Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Antiretroviral Therapy ART naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR Subjects will receive 24 weeks of therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None